ReCode develops targeted, disease-modifying medicines for patients with life-limiting respiratory diseases. The company's lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode has raised a total of $260 million in funding through its Series B extension (September 2023).
Cyborg Score Rationale
ReCode possesses a differentiated precision delivery platform with clinical validation in respiratory diseases. The company has secured substantial funding ($260M+ as of September 2023), strategic partnerships with Bayer/AskBio, and FDA orphan drug designations (March 2025) supporting competitive positioning. Early Phase 1 dosing of lead candidate RCT2100 demonstrates clinical progress in underserved CF patient populations.
Top Insights
(March 2025) RCT2100 received FDA Orphan Drug Designation for cystic fibrosis, targeting the 10-13% of CF patients with Class I CFTR mutations resistant to current modulators
(May 2026) Phase 1 clinical study underway with first healthy volunteer participants dosed with inhaled mRNA therapy RCT2100 for cystic fibrosis
(January 2023) Strategic collaboration with AskBio (Bayer subsidiary) to develop single-vector gene-editing platform combined with ReCode's SORT LNP delivery technology
(November 2024) Received additional funding from the Cystic Fibrosis Foundation to accelerate development of CF therapeutics
Named Competitors
mRNA Therapeutics Platform — mRNA-based vaccines and therapeutics platform
CFTR Modulators — CFTR modulators for cystic fibrosis treatment
mRNA Therapeutics — Individualized neoantigen therapy and mRNA platform